home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 11/06/23

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Expected earnings - Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc. (AQST) is expected to report $-0.11 for Q3 2023
AQST - Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the refinancing of its existing ...

AQST - Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

WARREN, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...

AQST - Aquestive Therapeutics weighs raising 2023 outlook

2023-10-09 10:20:46 ET More on Aquestive Therapeutics ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q2 - Re...
AQST - ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

2023-09-22 19:18:44 ET Summary Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-injectors). At current prices I expect that upside ...

AQST - Aquestive spikes as FDA rejects ARS Pharma's epinephrine spray

2023-09-20 12:35:22 ET More on Aquestive Seeking Alpha’s Quant Rating on Aquestive Therapeutics Historical earnings data for Aquestive Therapeutics Financial information for Aquestive Therapeutics Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Ca...

AQST - Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm(TM) (epinephrine) Sublingual Film

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the developm...
AQST - BHC, PL and ATRA are among pre market gainers

2023-09-20 08:29:58 ET Exscientia ( EXAI ) +30% climbs as Merck KGaA joins AI drug discovery. Regulus Therapeutics  ( RGLS ) +16% Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose  Clinical Trial o...

AQST - Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant(TM) (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of age Prescription Drug User Fee Act (PDUFA) target goal date set for April 28, 2024 WARREN, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aquestive ...

AQST - Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript

2023-08-08 10:45:02 ET Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Conference Call August 08, 2023, 08:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice Presiden...
Previous 10 Next 10